LKB1 reduces ROS-mediated cell damage via activation of p38

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Liver kinase B1 (LKB1), also known as serine/threonine kinase 11 (STK11), is a known tumor suppressor.
• Mutations in LKB1 are associated with Peutz-Jeghers syndrome and various sporadic cancers.

Purpose of the Study:

• To investigate the role of LKB1 in controlling intracellular reactive oxygen species (ROS) and protecting the genome from oxidative damage.
• To elucidate the molecular mechanisms by which LKB1 suppresses ROS accumulation and DNA damage.

Main Methods:

• Cellular assays to measure ROS levels, DNA oxidation, and mutation rates.
• Ectopic expression of LKB1 and treatment with antioxidants (N-acetylcysteine).
• Analysis of LKB1 interaction with the cdc42-PAK1 complex and downstream signaling pathways (p38, ATF-2).
• Assessment of antioxidant enzyme activity (superoxide dismutase-2, catalase).

Main Results:

• Cells lacking LKB1 exhibit significantly increased intracellular ROS levels, DNA oxidation, and mutation rates.
• Ectopic LKB1 expression and antioxidant treatment effectively prevent ROS accumulation and DNA damage.
• LKB1's ROS-suppressing function is independent of AMP-activated protein kinase.
• LKB1 binds to and activates the cdc42-PAK1 complex, leading to p38 and ATF-2 activation.
• This pathway enhances the activity of antioxidant enzymes superoxide dismutase-2 and catalase.

Conclusions:

• LKB1 plays a critical, non-canonical role in suppressing ROS and protecting the genome from oxidative damage.
• The LKB1-cdc42-PAK1-p38-ATF-2 pathway enhances antioxidant enzyme activity, mitigating ROS-induced damage.
• Targeting ROS signaling presents a potential therapeutic strategy for cancers with LKB1 deficiency.